Marc, founding CEO of Antabio, is a molecular and cellular microbiologist with over 25 years’ experience in academia and biotech. Prior to founding Antabio, Marc held different research positions at various institutions globally such as CNRS and Inserm (France), CSIC (Spain) and Emory University (USA), authoring over 20 peer-reviewed articles in the field of bacterial pathogenesis and antibiotic resistance. Under Marc’s leadership, Antabio has raised €44m funding and received numerous awards including CARB-X and Wellcome Trust (twice). Marc is a member of the Board of the BEAM Alliance (European Alliance of Biopharmaceutical companies combating Anti-Microbial resistance), and a member of the SAB of JPIAMR (the Joint Programming Initiative on Antimicrobial Resistance).
Speaking In
10:30 AM - 10:45 AM (EST)
Monday, February 6
Antabio is developing a pipeline of novel antibacterial drugs targeting WHO critical priority…
Winter Garden